Table 2 Clinical outcomes during follow-up
Variable | All patients (n = 400) |
|---|---|
Length of follow-up, n (%) | 400 (100) |
Median, years (IQR) | 16 (9–24) |
Use of RAAS inhibitor during follow-up, n (%) | 392 (98) |
Yes | 272 (69) |
No | 120 (31) |
Use of corticosteroids during follow-up, n (%) | 394 (99) |
Yes | 78 (20) |
No | 313 (78) |
Use of SGLT2 inhibitor during follow-up, n (%) | 396 (99) |
Yes | 28 (7) |
No | 368 (92) |
Time-averaged proteinuria (g/24 h), n (%) | 341 (85) |
Median (IQR) | 1 |
Proportion of follow-up period with proteinuria < 1 g/24 h, n (%) | 341 (85) |
Median, % (IQR) | 67 (22–90) |
Proportion of measurements with proteinuria < 1 g/24 h, n (%) | 341 (85) |
Median, % (IQR) | 71 (43–92) |
ESKD or death event, n (%) | 400 (100) |
Yes | 135 (34) |
No | 265 (66) |
Death event, n (%) | 400 (100) |
Yes | 69 (17) |
No | 331 (83) |
Death event without KRT, n (%) | 69 (17) |
Yes | 34 (49) |
No | 35 (51) |
ESKD, n (%) | 400 (100) |
Yes | 101 (25) |
No | 299 (75) |
KRT, n (%) | 400 (100) |
Yes | 99 (25) |
No | 301 (75) |
First event, n (%) | 133 (33) |
Death | 34 (25.6) |
Dialysis | 78 (58.6) |
Transplant | 21 (15.8) |
Years until first event, n (%) | 135 (34) |
Median, years (IQR) | 8 (5–14) |
Age at first event, n (%) | 135 (34) |
Median, years (IQR) | 57 (40–68) |
Survival rate (have not reached death or KRT), estimate (95% CI), n (%) | 400 (100) |
5-year | 91 (88–93) |
10-year | 79 (76–84) |
15-year | 73 (69–78) |
20-year | 67 (62–72) |
25-year | 62 (56–68) |
30-year | 55 (49–63) |
Quartile survival estimate, years (95% CI), n (%) | 400 (100) |
90% | 6 (4–7) |
80% | 10 (8–14) |
70% | 18 (15–23) |
60% | 27 (23-NE) |
50% | NE (29-NE) |